Literature DB >> 33813863

Which Acute Ischemic Stroke Patients Are Fast Progressors?: Results From the ESCAPE Trial Control Arm.

Johanna M Ospel1,2, Michael D Hill1,3, Manon Kappelhof4, Andrew M Demchuk1,3, Bijoy K Menon1,3, Arnuv Mayank1, Dar Dowlatshahi5, Don Frei6, Jeremy L Rempel7, Blaise Baxter8, Mayank Goyal1,3.   

Abstract

BACKGROUND AND
PURPOSE: Fast infarct progression in acute ischemic stroke has a severe impact on patient prognosis and benefit of endovascular thrombectomy. In this post hoc analysis of the ESCAPE trial (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke), we identified acute ischemic stroke patients with rapid infarct growth and investigated their baseline clinical and imaging characteristics.
METHODS: Control arm patients were included if they had follow-up imaging at 2-8 hours without substantial recanalization, and if their baseline Alberta Stroke Program Early CT Score was ≥9. Fast infarct progression was defined as Alberta Stroke Program Early CT Score decay ≥3 points from baseline to 2- to 8-hour follow-up imaging. Clinical and imaging baseline characteristics were compared between fast progressors and other patients, and occlusion site and collateral flow patterns were assessed in detail.
RESULTS: Fast infarct progression occurred in 15 of 43 included patients (34.9%). Fast progressors had worse collaterals (poor in 3/15 [20%] versus 0/28 patients, P=0.021) and more carotid-T or -L occlusions (8/15 [53.4%] versus 3/28[10.7%], P=0.021). In 8 out of 15 (53.3%), occlusion site and circle of Willis configuration prevented collateral flow via the anterior or posterior cerebral artery.
CONCLUSIONS: Most patients with fast infarct progression had terminal carotid occlusions and impaired collateral flow via the anterior or posterior cerebral artery, indicating that occlusion location and intracranial vascular anatomy are relevant for infarct progression.

Entities:  

Keywords:  circle of Willis; ischemic stroke; posterior cerebral artery; prognosis; thrombectomy

Mesh:

Year:  2021        PMID: 33813863     DOI: 10.1161/STROKEAHA.120.032950

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

Review 1.  Collateral Status and Outcomes after Thrombectomy.

Authors:  Jin Soo Lee; Oh Young Bang
Journal:  Transl Stroke Res       Date:  2022-06-10       Impact factor: 6.829

2.  Association between Early Ischemic Changes and Collaterals in Acute Stroke: A Retrospective Study.

Authors:  M Laflamme; S Carrondo-Cottin; M-M Valdès; D Simonyan; M-È Audet; J-L Gariépy; M-C Camden; C Gariépy; S Verreault; P Lavoie
Journal:  AJNR Am J Neuroradiol       Date:  2022-09-22       Impact factor: 4.966

Review 3.  Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era.

Authors:  Marc Fisher; Sean I Savitz
Journal:  Nat Rev Neurol       Date:  2022-01-25       Impact factor: 44.711

4.  Effectiveness and safety of EVT in patients with acute LVO and low NIHSS.

Authors:  Beom Joon Kim; Bijoy K Menon; Joonsang Yoo; Jung Hoon Han; Bum Joon Kim; Chi Kyung Kim; Jae Guk Kim; Joon-Tae Kim; Hyungjong Park; Sung Hyun Baik; Moon-Ku Han; Jihoon Kang; Jun Yup Kim; Keon-Joo Lee; Jong-Moo Park; Kyusik Kang; Soo Joo Lee; Jae-Kwan Cha; Dae-Hyun Kim; Jin-Heon Jeong; Tai Hwan Park; Sang-Soon Park; Kyung Bok Lee; Jun Lee; Keun-Sik Hong; Yong-Jin Cho; Hong-Kyun Park; Byung-Chul Lee; Kyung-Ho Yu; Mi-Sun Oh; Dong-Eog Kim; Wi-Sun Ryu; Kang-Ho Choi; Jay Chol Choi; Joong-Goo Kim; Jee-Hyun Kwon; Wook-Joo Kim; Dong-Ick Shin; Kyu Sun Yum; Sung-Il Sohn; Jeong-Ho Hong; Chulho Kim; Sang-Hwa Lee; Juneyoung Lee; Mohammed A Almekhlafi; Andrew Demchuk; Hee-Joon Bae
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

5.  Identification of Differentially Expressed microRNAs Associated with Ischemic Stroke by Integrated Bioinformatics Approaches.

Authors:  Shengqiang Jiang; Jie Wu; Yan Geng; Yuting Zhang; Yupeng Wang; Jinrong Wu; Chunqu Lu; Guoxuan Luo; Jie Zan; Yong Zhang
Journal:  Int J Genomics       Date:  2022-10-10       Impact factor: 2.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.